Skip to main content
Equibles
TXMD logo

TXMD · TherapeuticsMD, Inc. · Metrics

Track TXMD — free

Use TXMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TXMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.75 -0.07 (-3.85%) Q2 2022 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”
View the 10-Q filed Aug 11, 2026
Customer concentration — top 3 customers 100% of revenue

3 customers — 100% of revenue (the three and six months ended June 30, 2026)

“For the three and six months ended June 30, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
View the 10-Q filed Aug 11, 2026
Market Cap
$21.07M
Shares
11.57M
Volume · Nov 5 3554 Avg daily vol (3M) 23.41K

TXMD metrics

72 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.82
Market cap
$21.07M

Price action

20 metrics
Price change (1W)
+0.0%
Price change (30D)
-11.4%
Price change (3M)
-12.7%
Price change (6M)
-14.0%
Price change (YTD)
+9.2%
Price change (1Y)
+54.8%
Trailing year
Price change (5Y)
—
52-week high
$2.77
52-week low
$1.15
Change from 52-week high
-35.7%
Change from 52-week low
+54.8%
Annualized volatility
72.9%
Annualized volatility (3M)
33.5%
Beta
0.2
RSI (14D)
32.4
Price vs SMA 50
-12.8%
Price vs SMA 200
-15.7%
Avg volume (3M)
23,317
Relative volume
0.3
Average dollar volume
$48,729

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
11.57M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
6.3×
reciprocal yield 15.8%
P / book
0.8
reciprocal yield 131.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
6.7
reciprocal yield 15.0%
Earnings yield
-1.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.9×
reciprocal yield 34.7%
EV / revenue historical average (5Y)
3.9×
reciprocal yield 25.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2022-11-14

Profitability

9 metrics
Gross margin
—
Operating margin
-120.9%
Trailing 12 months
Net margin
-6.6%
Gross profit (TTM)
$1.30M
Operating profit (TTM)
−$3.95M
Net income (TTM)
−$217,000
Trailing 12 months
Diluted EPS (TTM)
$-0.02
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.63
Stock compensation per diluted share (TTM)
—
Book value per share
$2.32

Growth

11 metrics
Revenue growth YoY
-8.7%
Year over year
Net income growth YoY
-71.9%
Revenue (TTM)
$3.27M
Trailing 12 months
EPS growth YoY
-80.0%
Shares change YoY
+0.6%
Year over year · more shares
Revenue CAGR (3Y)
-64.9%
Revenue CAGR (5Y)
-45.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-0.8%
Return on assets
-0.6%
Debt / equity
—
Current ratio
3.2
EBITDA (TTM)
−$3.57M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$9.19M
Total assets
$37.53M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$3.10M
Capital expenditures (TTM)
$21,000
R&D (TTM)
$5.51M
SG&A (TTM)
$4.49M
Stock compensation (TTM)
$57,000
R&D / revenue
—
Stock compensation / revenue
1.7%

Ownership (13F)

9 metrics
13F filers
47
13F filer change QoQ
-3
Institutional ownership
31.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
24.4%
Private-fund adviser ownership
18.6%
Active holders' share change QoQ
-8.4%
Holder tenure
16.2
Price vs estimated holder cost
-42.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.9%

Short interest

3 metrics
Short interest
0.2%
Latest settlement · 1.4 days to cover
Days to cover
1.4d
Short-squeeze score
31 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 25743 CUSIP 88338N206 13F (30d) 10 filings 10 filers Visit website Investor relations